Figure 5.

Contrast-enhanced CT images and tumor markers in characteristic cases according to previous treatment (AFP, PIVKA-II). a. Pretreatment was lenvatinib. The tumor markers decreased after the start of treatment, but tumor size according to both RECIST and mRECIST was increased. However, the size decreased with continued treatment. b. Pretreatment was ramucirumab. Early after the start of treatment, tumor size according to both RECIST and mRECIST was decreased and tumor markers were also decreased, but liver atrophy occurred and ascites appeared. The patient improved after one course of withdrawal, but tumor markers and tumor size then both increased.mRECIST = modified response evaluation criteria in solid tumors, RECIST = response evaluation criteria in solid tumors.